This article is more than 5 years old. Information may no longer be current.
Eight recent developments involving aesthetic dermatology
Recent developments involving aesthetic dermatology included the FDA’s approval of Suneva’s Bellafill for treating acne scars and the release of the American Society of Dermatologic Surgery’s guidelines on sclerotherapy.
Research results presented in Healio Dermatology included onabotulinumtoxinA’s effectiveness in treating crow's feet lines and preventable measures that might help decrease biofilm formation:
1. FDA approves Suneva's Bellafill dermal filler for treatment of acne scars
Suneva Medical announced that the FDA has approved its dermal filler, Bellafill, for treating acne scars.
Ava Shamban
Bellafill is designed to add volume to the skin to smooth out pitted acne scars through an in-office injection procedure with little-to-no downtime, according to a company press release.
“In the dermatology field, we regularly see patients who live with the burden of acne scarring,” investigator Ava Shamban, MD, said in the release. “I look forward to using this proven treatment option with patients.” Read more
2. Actavis, Allergan announce SEC declaration, shareholder meetings on pending acquisition
Actavis and Allergan announced that the U.S. Securities and Exchange Commission has declared Actavis’ registration statement on Form S-4 with regard to Actavis’ pending acquisition of Allergan to be effective.
The two companies also announced in a press release that they have scheduled special shareholder meetings on March 10 in connection with the pending acquisition. Read more
3. Delayed reaction, biofilm formation after filler injection may decrease with preventive measures
Preventable measures may help decrease delayed reactions and biofilm formation after dermal filler injection, according to findings from a literature review.
Researchers reviewed relevant literature to gain an understanding of and explore the mechanism of action for biofilm formation, diagnostic challenges and methods for recognizing biofilms. Read more
4. OnabotulinumtoxinA effective in treating crow's feet lines, glabellar lines
Jean Carruthers
OnabotulinumtoxinA was effective and well-tolerated as a repeated treatment in patents with moderate-to-severe crow’s feet lines alone or combined with glabellar lines, according to published study results.
Jean Carruthers, MD, and colleagues conducted a multicenter, double-blind, 7-month study of 917 patients with moderate-to-severe crow’s feet lines and glabellar lines. Read more
5. ASDS releases consensus document on sclerotherapy
Appropriate patient evaluation, proper choice of technique and post-procedure compression are essential to successful sclerotherapy for varicose and telangiectatic leg veins, according to consensus guidelines issued by the American Society of Dermatologic Surgery. Read more
6. FDA approves phase 3 study protocol for Evosyal
Alphaeon Corporation announced that the FDA has approved the protocol for its phase 3 clinical study of Evosyal for the treatment of glabella lines.
The company acquired exclusive U.S. and certain international distribution rights for Evosyal (botulinum toxin Type A neuromodulator) through its acquisition of Evolus. Read more
7. Changing pH in botulinum toxin Type B reduced injection pain
By changing the pH level in the acidic solution of botulinum toxin Type B, injection pain was reduced and efficacy was not compromised, according to study results.
Researchers used reviewed clinical evaluation data and computer analysis of photographs to confirm the efficacy of different dilutions of botulinum toxin Type Band to confirm botulinum toxin Type A resistance in a series of three patients. Read more
8. Galderma launches Restylane Silk lip enhancement, wrinkle treatment
Galderma announced the launch of its FDA-approved filler, Restylane Silk, which is indicated for lip enhancement and for the treatment of wrinkles around the mouth in patients 21 years and older.
Restylane Silk is a smooth gel designed to restore natural youthful definition and symmetry to the lip and mouth area, according to a company press release. Read more